The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FDA approves pirtobrutinib for patients with relapsed/refractory CLL/SLL
On December 1, 2023, it was announced that the U.S. Food and Drug Administration (FDA) had approved pirtobrutinib, a selective non-covalent Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) after ≥2 lines of therapy, including a B-cell lymphoma 2 inhibitor and BTKi. This decision is based on promising overall response and duration of response rates from the phase I/II BRUIN (NCT03740529).1
BRUIN trial
BRUIN is a phase I/II open-label study evaluating pirtobrutinib in patients with R/R CLL/SLL.1 The Lymphoma Hub previously reported the trial design and promising results (Figure 1).
Figure 1. BRUIN trial outcomes in patients with R/R CLL/SLL (n = 108)*
ORR, overall response rate.
*Adapted from PR Newswire.1
Conclusion
The approval of pirtobrutinib provides patients with R/R CLL/SLL another treatment option that could potentially benefit their patient journey.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content